ANX007

About Annexon Biosciences

Annexon Biosciences is developing first-in-class C1q inhibitors to halt the classical complement pathway, a key driver of tissue damage in severe diseases of the body, brain, and eye. Founded on groundbreaking research from Stanford, the company has built a versatile platform with multiple drug candidates in late-stage clinical trials, including ANX005 for GBS and ANX007 for geographic atrophy. Its strategy focuses on achieving functional clinical benefits in areas of high unmet need, positioning it as a leader in upstream complement inhibition with significant near-term catalysts.

About Annexon Biosciences

Annexon Biosciences is developing first-in-class C1q inhibitors to halt the classical complement pathway, a key driver of tissue damage in severe diseases of the body, brain, and eye. Founded on groundbreaking research from Stanford, the company has built a versatile platform with multiple drug candidates in late-stage clinical trials, including ANX005 for GBS and ANX007 for geographic atrophy. Its strategy focuses on achieving functional clinical benefits in areas of high unmet need, positioning it as a leader in upstream complement inhibition with significant near-term catalysts.

About Annexon

Annexon is a leader in developing C1q-targeting monoclonal antibodies to inhibit the classical complement pathway, a key driver of inflammation and neurodegeneration. Founded on seminal research from Stanford neurobiology, the company has built a late-stage pipeline with lead programs in Guillain-Barré Syndrome (GBS) and Geographic Atrophy (GA). Its strategy focuses on achieving functional benefits for patients by blocking complement activation upstream, potentially offering a more comprehensive and selective therapeutic profile than downstream inhibitors.

About Annexon

Annexon is a leader in developing C1q-targeting monoclonal antibodies to inhibit the classical complement pathway, a key driver of inflammation and neurodegeneration. Founded on seminal research from Stanford neurobiology, the company has built a late-stage pipeline with lead programs in Guillain-Barré Syndrome (GBS) and Geographic Atrophy (GA). Its strategy focuses on achieving functional benefits for patients by blocking complement activation upstream, potentially offering a more comprehensive and selective therapeutic profile than downstream inhibitors.

Therapeutic Areas

Other Geographic Atrophy (GA) Drugs